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OBJECTIVES We sought to describe the relationship between cholesterol and survival in patients with
chronic heart failure (CHF).
BACKGROUND Increasing lipoprotein levels are a cardiovascular risk factor. In patients with CHF, the
prognostic value of endogenous lipoproteins is not fully clarified.
METHODS A group of 114 patients with CHF recruited to a metabolic study was followed for a
minimum of 12 months (derivation study). The results were applied to a second group of 303
unselected patients with CHF (validation study). The relationship between endogenous
lipoproteins and survival was explored.
RESULTS In the derivation study, survival at 12 months was 78% (95% confidence interval [CI] 70% to
86%) and 56% (95% CI 51% to 62%) at 36 months. Increasing total serum cholesterol was
a predictor of survival (hazard ratio 0.64, 95% CI 0.48 to 0.86), independent of the etiology
of CHF, age, left ventricular ejection fraction, and exercise capacity. Receiver-operating charac-
teristic curves demonstrated a best cut-off value of 5.2 mmol/l (200.8 mg/dl) as being the best
predictor of mortality at 12 months (sensitivity 80.0%, specificity 62.9%). In the validation
population, one-year survival was 88% (95% CI 84 to 91%) and three-year survival was 68% (95%
CI 63 to 73%). The chance of survival increased 25% for each mmol/l increment in total
cholesterol. Survival rates above and below the cut-off value for cholesterol in patients with
ischemic heart disease (n  181) were 92% (95% CI 89 to 94) versus 75% (95% CI 64 to 85%)
at one year and 72% (95% CI 67 to 76%) versus 50% (95% CI 43 to 56%) at three years.
CONCLUSIONS In patients with CHF, lower serum total cholesterol is independently associated with a worse
prognosis. (J Am Coll Cardiol 2003;42:1933–40) © 2003 by the American College of
Cardiology Foundation
Coronary heart disease is a world-wide health care problem.
Cholesterol is a major adverse risk factor for the develop-
ment of coronary heart disease, and cholesterol reduction
therapy with 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors (statins) has been shown
to be beneficial in both primary and secondary prevention of
coronary heart disease (1,2). The risk of developing chronic
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heart failure (CHF) is strongly associated with the presence
of coronary heart disease (3,4), and the use of a statin has
been shown to prevent the development of new-onset CHF
(5). There is, however, no evidence of either a benefit or
harm with statin therapy in patients who have already
developed CHF. There are theoretical concerns about
statins in CHF (6), and the presence of CHF was an
exclusion criterion in all of the landmark statin studies. The
relationship between cholesterol and survival in CHF has
not been fully established.
We have hypothesized that low serum cholesterol may be
a marker of impaired prognosis in patients with CHF (7).
Patients with CHF have a diffuse increase in indices of
immune activity, which is potentially linked to higher than
normal levels of endotoxin (8). Lipoproteins are natural
nonspecific buffers of endotoxin; binding to endotoxin
(lipopolysaccharide [LPS]) leads to reduced LPS bioactivity
and to diminished immune activation. Preliminary reports
have suggested that there is an increased mortality in CHF
patients with low cholesterol (9,10). A more recent article
has confirmed these findings in a larger population (11).
The objective of the present study was to explore and
validate the relationships between cholesterol and triglycer-
ide levels and all-cause mortality in a large CHF population.
METHODS
Study population. All patients with CHF were recruited
from the Royal Brompton Hospital Chronic Heart Failure
and Cardiomyopathy Clinic. The studies were approved by
the local ethics committee, and all participants had given
written, informed consent. The diagnosis of CHF was
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based on standard criteria (12). The duration of CHF was
between 6 months and 20 years. Cardiac cachexia was
defined as weight loss 7.5% over a period of more than six
months, as described previously (13). We first investigated a
population of patients who had undergone metabolic eval-
uation to explore the relationship between cholesterol and
mortality (derivation study), and then we applied this to a
wider group of patients with CHF (validation study).
Derivation study. Between January 1992 and July 1999,
we recruited 114 CHF patients (New York Heart Associ-
ation [NYHA] functional class I/II/III/IV: 11/34/54/15; 4
females) into our metabolic study programs, aiming at
one-third of the patients being cachectic (n  38). Patients
were excluded from the study if they had clinical signs of
acute infection, rheumatoid disease, or myocardial infarc-
tion within the previous 12 months, or if there was a clinical
suspicion of a malignant or primary wasting disorder.
Patients with metabolic disorders affecting lipoprotein me-
tabolism (e.g., thyroid disease, severe liver disease) or those
with excessive alcohol intake were also excluded. Effectively,
no patient was excluded based on a criterion of no myocar-
dial infarction within the previous 12 months. If a patient
was not studied in the derivation study, he or she could still
have been included in the validation study. If a patient had
several metabolic assessments, the earliest available infor-
mation was used.
All patients performed a maximal treadmill exercise test
(modified Bruce protocol, Amis 2000, Odense, Denmark)
for measurement of peak oxygen consumption (VO2, ml/kg
per min) and the slope of the relationship between ventila-
tion and carbon dioxide production (VE/VCO2 slope)
(14,15). Left ventricular ejection fraction (LVEF) was
measured by radionuclide ventriculography. All patients
were treated with medical therapy thought to be optimal for
their individual CHF profile at that time. Overall, patients
received diuretics (94%), angiotensin-converting enzyme
inhibitors (91%), aspirin (53%), digoxin (40%), nitrates
(37%), amiodarone (26%), statins (18%), calcium channel
antagonists (11%), and beta-blockers (4%) in varying com-
binations.
On the assessment day, blood samples (25 ml) were
collected between 9 and 10 AM, after an overnight fast of at
least 12 h. Blood was drawn following supine rest for at least
20 min. Serum samples for the measurement of lipoproteins
and routine biochemical variables were analyzed within 1 h.
Plasma aliquots, following immediate centrifugation, were
stored at 70°C until analysis. Plasma concentrations of
soluble tumor necrosis factor receptor type 1 (sTNF-R1,
sensitivity 25 pg/ml) were determined by a sandwich
ELISA from R&D Systems (Minneapolis, Minnesota)
(16). All other biochemical analyses were performed using
routine hospital analyses.
Validation study. To assess the validity of our findings, we
recruited a second independent population of patients with
CHF. This population consisted of outpatients who were
not recruited into metabolic studies, but in whom nonfast-
ing serum levels of total cholesterol and high-density
lipoprotein (HDL) cholesterol had been determined as part
of the routine outpatient procedure between January 1993
and June 1999 (n  303). If a patient had several assess-
ments, the earliest available information was used. We
tested the predictive power of total cholesterol and HDL
levels using the results from the derivation study.
Follow-up. Patients in both the derivation and validation
studies were followed up by outpatient assessments, by
telephone contact between the patient or his or her local
physician, or through the Hospital Information System in
July 2000. Survival status was also obtained from the Office
of National Statistics, where all patients had been flagged
for death as part of the Royal Brompton Hospital Chronic
Heart Failure Registry. The primary end point of the study
was all-cause mortality. Follow-up was censored at 36
months.
Determination of lipoproteins. Serum total cholesterol,
HDL cholesterol, and triglyceride levels were measured by
routine hospital analyses (SYNCHRON CX Systems CX
MULI Calibrator, Beckman Coulter, Inc., Fullerton, Cal-
ifornia). Low-density lipoprotein (LDL) cholesterol was
also calculated (17). Assessments of lipoproteins were per-
formed at the beginning of the follow-up period.
Statistical analysis. Data are expressed as the mean value
 SE. Normality of distribution for continuous variables
was tested using the Kolmogorov-Smirnov test. The un-
paired Student t test was used to compare mean values
between groups. Proportions were compared using the
chi-square and Fisher exact test. Cox proportional hazards
analyses were used to assess prognostic associations. The
hazard ratio (HR) with 95% confidence interval (CI) and p
values by the likelihood ratio test are presented. Hazard
ratios for continuous variables apply per unit of the analyzed
variable. Kaplan-Meier cumulative survival plots were con-
structed to illustrate the results (StatView version 5.0,
Abacus Concepts, Berkeley, California).
To compare different predictive values at a particular time
Abbreviations and Acronyms
CHF  chronic heart failure
CI  confidence interval
HDL  high-density lipoprotein
HMG-CoA  3-hydroxy-3-methylglutaryl coenzyme A
HR  hazard ratio
LDL  low-density lipoprotein
LPS  lipopolysaccharide
LVEF  left ventricular ejection fraction
ROC  receiver-operating characteristics
sTNF-R1  soluble tumor necrosis factor receptor
type 1
VO2  oxygen consumption
VE/VCO2 slope  slope of the relationship between
ventilation and carbon dioxide
production
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point, areas under the curve for sensitivity and specificity
were constructed. The best prognostic cut-off value for
survival status at a given time point was defined as that
which gave the highest product of sensitivity and specificity
(MedCalc, version 5.0, MedCalc Software, Mariakerke,
Belgium). For both sets of patients, the analysis was
retrospective.
RESULTS
Derivation study. The characteristics of the patients at
baseline and after subgrouping into survivors and nonsurvi-
vors are given in Table 1. A minimum follow-up of 12
months (mean 31 0.9 months, median 36, range 12 to 36)
was achieved for survivors. Survival at 12 months was 78%
(95% confidence interval [CI] 70 to 86%) and 56% (95% CI
51 to 62%) at 36 months.
Total cholesterol was normally distributed (range 2.59
to 9.05 mmol/l) and was not related to NYHA class,
etiology of CHF (nonischemic: 5.3  0.2 mmol/l
[204.6  7.7 mg/dl]; ischemic: 5.2  0.1 mmol/l [200.8 
3.9 mg/dl]; p  0.7), the presence of cachexia (cachectic:
5.0 0.2 mmol/l [193.1 7.7 mg/dl]; noncachectic: 5.4
0.1 mmol/l [208.5  3.9 mg/dl]; p  0.07), or age (r 
0.009, p  0.9). There were no differences in LDL
cholesterol or triglycerides between those with ischemic
heart disease and those without (p  0.2), but the
patients with ischemic heart disease had a lower HDL
cholesterol level (1.2  0.0 mmol/l [46.3  2.1 mg/dl] vs.
1.3  0.1 mmol/l [50.2  3.9 mg/dl]; p  0.04).
Cachectic CHF patients (n  38) did not differ from
noncachectic patients with regard to serum total, LDL, and
HDL cholesterol (all p  0.07), but they had lower
triglycerides (1.4  0.1 vs. 1.9  0.1 mmol/l [123.9  8.9
vs. 168.2  8.9 mg/dl], p  0.02). Cholesterol was related
to body mass index (r  0.28, p  0.003). This relationship
was significant only in noncachectic patients (r  0.26, p 
Table 1. Clinical and Biochemical Characteristics of Patients in the Derivation Study
Variable
All Patients
(n  114)
12 Months 36 Months
Nonsurvivors
(n  25)
Survivors
(n  89)
Nonsurvivors
(n  39)
Survivors
(n  50)
Age (yrs) 63.0  1.0 66.3  2.2 61.6  1.1 66  1.5¶ 58  1.5
BMI (kg/m2) 24.8  0.4 23.4  0.8 25.2  0.5 23.7  0.6† 25.6  0.6
Mean arterial pressure (mm Hg) 88.4  1.2 88.0  3.0 88.5  1.3 87.8  2.5 88.0  1.7
Sodium (mmol/l) 137.0  0.3 135.7  0.9 137.2  0.3 135.7  0.6§ 137.7  0.4
Potassium (mmol/l) 4.0  0.04 4.0  0.12 4.0  0.04 4.1  0.09 3.9  0.04
ESR (mm/h) 22  2 30.7  5.4† 19.6  1.8 29.7  4¶ 15.0  1.6
sTNF-R1 (pg/ml) 1,495  90 2,207  196‡ 1,295  92 2,081  145‡ 992  99
BUN (mmol/l) 4.8  0.3 7.1  0.6‡ 4.2  0.3 6.7  0.5‡ 3.6  0.3
Peak VO2 (ml/kg per min) 17.0  0.6 11.2  0.8‡ 18.1  0.7 12.4  0.6‡ 19.7  0.9
VE/VCO2 slope 39.3  1.4 48.7  3.6§ 37.3  1.5 48.6  2.9‡ 33.2  1.7
LVEF (%) 29.0  1.0 20.6  2.4§ 31.5  1.6 23.2  2.2§ 30.2  2.2
Total cholesterol (mmol/l) 5.2  0.1 4.56  0.20¶ 5.44  0.12 4.90  0.16§ 5.70  0.16
HDL cholesterol (mmol/l) 1.2  0.04 1.2  0.1 1.2  0.0 1.2  0.1 1.2  0.1
LDL cholesterol (mmol/l) 3.3  0.1 2.80  0.16§ 3.39  0.11 3.02  0.14§ 3.65  0.14
Triglycerides (mmol/l) 1.7  0.1 1.2  0.1§ 1.9  0.2 1.5  0.1† 2.0  0.2
NYHA class* (n)
I 11 0 11 0 9
II 34 3 31 7 16
III 54 14 40 21 22
IV 15 8 7 11 3
Etiology (%)
IHD 62 56 64 64 56
DCM 38 44 36 36 44
Cachexia (%) 33 60 26* 54 24*
Medication (%)
Loop diuretic 90 92 90 95 92
ACE inhibitor 91 88 92 90 96
Calcium channel blocker 11 9 11 8 14
Digoxin 40 44 39 51 40
Amiodarone 26 20 28 28 28
Beta-blocker 4 0 4 0 4
Lipid lowering 18 16 19 10 14
Aspirin 53 44 55 44 54
*p  0.01 survivors versus nonsurvivors by the Fisher exact test; †p  0.05, ‡p  0.0001, §p  0.01, ¶p  0.001 survivors versus nonsurvivors. The difference in NYHA class
distribution was significant at both time points. Data are presented as the mean value  SEM or number or percentage of subjects.
ACE  angiotensin-converting enzyme; BMI  body mass index; BUN  blood urea nitrogen; DCM  dilated cardiomyopathy; ESR  erythrocyte sedimentation rate;
HDL and LDL  high- and low-density lipoprotein, respectively; IHD  ischemic heart disease; LVEF  left ventricular ejection fraction; NYHA  New York Heart
Association; VE/VCO2  relationship between ventilation and carbon dioxide production; VO2  oxygen consumption.
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0.02). An inverse correlation was found between serum
cholesterol and sTNF-R1 (r0.27, p 0.005) and, after
subgrouping, in cachectic CHF patients (r  0.45, p 
0.005), but not in noncachectic patients. Patients with
serum cholesterol below the median value (5.31 mmol/l
[205.0 mg/dl]) had significantly higher plasma concentra-
tions of sTNF-R1 (1,585  123 vs. 1,113  91 pg/ml, p 
0.002).
Univariate predictors of survival at 36 months are given in
Table 2. We confirmed the predictors commonly reported,
including high concentrations of sTNF-R1 (16) and the
presence of cardiac cachexia (13). Duration of CHF was not
a mortality predictor. Low serum cholesterol predicted
increased mortality. There was a 36% increase in the risk of
death within three years for every mmol/l decrease in serum
cholesterol. The survival for quartiles of cholesterol is shown
in Figure 1. Triglycerides and LDL cholesterol also pre-
dicted survival (Table 2), but not HDL cholesterol (p 
0.8).
To explore the predictive power of cholesterol indepen-
dent of established prognostic indicators, bivariate analyses
demonstrated that low serum cholesterol predicted in-
creased mortality independent of peak VO2, LVEF, sTNF-
R1, age, and CHF etiology (Table 2). In each of these
analyses, cholesterol was a predictor independent of age and
etiology of CHF. On multivariate analysis, sTNF-R1,
LVEF, peak VO2, and cholesterol jointly predicted CHF
mortality independent of age (p 0.7) and CHF etiology (p
 0.7). Triglycerides and LDL cholesterol were not pre-
dictors independent of total cholesterol.
The same variables predicted survival to one year (HR
[95% CI]): peak VO2 0.75 (0.66 to 0.85), p  0.0001;
sTNFR-1: 1.0006 (1.0003 to 1.0009), p  0.0001; choles-
terol: 0.53 (0.37 to 0.76), p  0.0005; and LVEF: 0.95
(0.91 to 0.98), p  0.003. On multivariate analysis, all four
variables were independent predictors of survival with a
combined chi-square statistic of 60.6 (p  0.0001).
Receiver-operating characteristic (ROC) curve analysis
identified a cholesterol level5.20 mmol/l (200.8 mg/dl) as
being the best predictor of mortality at both 12 (sensitivity
Table 2. Predictors of Survival at 36 Months in Chronic Heart Failure Patients Derivation
Study
Variable
Hazard Ratio
(95% CI) p Value
Chi-Square
Value
Joint Chi-Square
Value
Univariate analyses
Peak VO2 0.77 (0.70–0.84) 0.0001 44.6
VE/VCO2 slope 1.04 (1.02–1.05) 0.0001 16.6
Total cholesterol 0.64 (0.48–0.86) 0.002 9.2
LDL 0.67 (0.48–0.93) 0.02 5.86
TG 0.63 (0.42–0.96) 0.02 5.67
HDL 0.91 (0.42–2.0) 0.82 0.05
Age 1.04 (1.01–1.08) 0.006 7.47
Cachexia 3.07 (1.63–5.77) 0.0006 11.83
LVEF 0.96 (0.94–0.99) 0.001 10.46
sTNF-R1 1.0006 (1.0004–1.0008) 0.0001 20.7
Bivariate analyses
Peak VO2 0.79 (0.72–0.86) 0.0001 27.8 51.6
Cholesterol 0.68 (0.51–0.91) 0.009 6.8
LVEF 0.95 (0.93–0.98) 0.0004 12.5 24.1
Cholesterol 0.54 (0.39–0.76) 0.0003 12.9
sTNF-R1 1.0007 (1.0006–1.001) 0.0001 28.5 32.9
Cholesterol 0.63 (0.48–0.83) 0.0009 11.1
Multivariate analysis
sTNFR-1 1.00008 (1.0004–1.001) 0.0001 21.2 74.1
Peak VO2 0.83 (0.76–0.90) 0.0001 17.4
LVEF 0.96 (0.93–0.99) 0.003 9.0
Cholesterol 0.61 (0.11–0.85) 0.003 8.6
CI  confidence interval; TG  triglycerides; other abbreviations as in Table 1.
Figure 1. Survival in the derivation study with patients classified into
quartiles of total cholesterol (quartile 1 being the lowest; 4 the highest).
Log-rank p  0.0016 for the differences between quartiles.
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80.0%, specificity 62.9%) and 36 months (sensitivity 61.5%,
specificity 74%).
Validation study. Clinical data for the 303 CHF patients
in the validation study are shown in Table 3. One-year
survival was 88% (95% CI 84 to 91%) and three-year
survival was 68% (95% CI 63 to 73%). All survivors were
followed for a minimum of 12 months (average 33.4,
median 36). There were 91 deaths. Serum total cholesterol
(5.6  1.2 mmol/l [range 2.4 to 9.0]; 216.0  46.3 mg/dl
[range 92.7 to 347.5]) and HDL cholesterol (1.1  0.4
mmol/l [range 0.4 to 3.1]; 42.5 15.0 mg/dl [range 42.5 to
119.7]) were normally distributed. Serum cholesterol was
not related to body mass index (r  0.01, p  0.44).
Cachectic and noncachectic patients did not differ in total
Table 3. Clinical Details of the Patients in the Validation Study
Variable
All Patients
(n  303)
12 Months 36 Months
Nonsurvivors
(n  38)
Survivors
(n  265)
Nonsurvivors
(n  91)
Survivors
(n  162)
Age (yrs) 62.1  0.7 64.7  1.8 61.7  0.7 64.0  1.2 60.6  0.9*
NYHA class (%)
I 17 6 18 6 24
II 43 37 44 34 46
III 31 31 31 37 27
IV 9 26 7† 23 3‡
Etiology (%)
IHD 60 68 58 68 59
DCM 40 32 42 34 41
Cachexia (%) 4.4 17 2.6‡ 12 0.7‡
Peak VO2 (ml/kg/min) (n  221) 17.3  0.4 15.1  1.1 17.6  0.4* 14.7  0.6 18.8  0.5‡
LVEF (%) (n  197) 30.4  1.1 21.7  1.8 31.5  1.2† 21.3  1.5 35.0  1.5‡
Total cholesterol (mmol/l) 5.59  0.07 5.01  0.20 5.67  0.08† 5.29  0.13 5.85  0.10‡
HDL cholesterol (mmol/l) 1.10  0.02 0.99  0.05 1.12  0.03 1.00  0.04 1.06  0.03
Medication (%)
Loop diuretic 81 88 80 85 80
ACE inhibitor 86 82 87 83 86
Calcium channel blocker 19 10 20 11 21
Digoxin 26 36 24 31 21
Amiodarone 17 10 18 13 12
Beta-blocker 8 6 8 2 12
Lipid lowering 20 12 21 11 21
Aspirin 53 61 55 38 60
The p values refer to comparisons between survivors and nonsurvivors at each time point: *p  0.05, †p  0.01, ‡p  0.001. Data are presented as the mean value  SEM or
percentage of subjects.
Abbreviations as in Table 1.
Table 4. Comparison of Patients Below and Above the Predetermined Cut-Off Value for
Cholesterol in the Validation Study
Variable
Cholesterol (mmol/l)
p Value
<5.2
(n  126)
>5.2
(n  177)
Age (yrs) 61.2  1.1 62.7  0.8 0.29
NYHA class (%) 0.21
I 16 17
II 39 46
III 31 30
IV 13 6
Etiology (%)
IHD 63 (50) 118 (67) 0.004
DCM 63 (50) 59 (33)
Cachexia (%) 5.4 3.7 0.52
Peak VO2 (ml/kg per min) (n  221) 16.7  0.7 17.7  0.5 0.25
LVEF (%) (n  197) 29.8  1.8 30.8  1.3 0.64
Total cholesterol (mmol/l) 4.42  0.05 6.41  0.06 —
One-year survival (%) 79 (72–86) 93 (89–97) 0.0013
Three-year survival (%) 59 (50–68) 75 (68–82) 0.0011
The p values refer to the unpaired t test for continuous variables and the chi-square test for discontinuous. The survival values
are from the log-rank test. The difference in cholesterol is “significant” by definition.
Abbreviations as in Table 1.
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cholesterol (5.3  0.5 vs. 5.6  0.1 mmol/l [204.6  19.0
vs. 216.2 3.9 mg/dl]) and HDL cholesterol levels (1.07
0.11 vs. 1.08  0.02 mmol/l [41.3  19.3 vs. 41.7  0.8
mg/dl], both p  0.2). Patients who died during follow-up
had a lower serum cholesterol level than survivors (Table 3).
Increasing serum cholesterol predicted improved survival
at 36 months (chi-square  10.4, p  0.001), independent
of age. The chance of survival increased 25% for each
mmol/l increment in total cholesterol (relative risk 0.75
[95% CI 0.63 to 0.90]). The patients were classified into
groups according to the previously determined best predic-
tor of mortality (5.20 vs. 5.2 mmol/l [200.8 mg/dl]).
Comparative data are shown in Table 4, and the Kaplan-
Meier survival plots are shown in Figure 2. Lower choles-
terol predicted a worse outcome. Cholesterol predicted
survival independent of age, LVEF, etiology, NYHA class,
and peak VO2 (Table 5).
Figure 3 shows the survival times in patients grouped by
underlying diagnosis. Although the study was not designed
to investigate the influence of lipid-lowering therapy on
survival from heart failure and the numbers involved were
very small (20% of patients), we did combine the two groups
for a single analysis of the effect of lipid-lowering therapy on
survival. Treatment was associated with a greater three-year
survival (82% [95% CI 77 to 87%] vs. 64% [95% CI 58 to
69%], chi-square 5.7, p 0.02). If the patients on statins
are removed from the analysis, the relationship between
cholesterol and survival is not materially altered (data not
shown).
To analyze the relationship between serum cholesterol
level and survival in the subgroups of cachectic and nonca-
chectic CHF patients, we combined the two data sets. In 50
cachectic CHF patients, 31 deaths were observed and
higher cholesterol levels related to longer survival (HR 0.71
[95% CI 0.53 to 0.91], p  0.021). Also in the 367
noncachectic patients (99 deaths during follow-up), higher
cholesterol levels related to longer survival (HR 0.75 [95%
CI 0.63 to 0.89], p  0.0011).
DISCUSSION
There is a host of factors related to prognosis in CHF.
These factors cluster around an index of exercise capacity
(such as VO2), an index of left ventricular function (such as
ejection fraction), and an index of metabolic activity (such as
cytokines). We have demonstrated a relationship between
cholesterol and survival in patients with CHF. First, we
explored the relationship between lipids and other variables
and outcome in a smaller group of patients with moderate to
severe CHF recruited into a metabolic study, and then we
applied the results to a larger cohort of patients with mild to
moderate CHF. The chance of survival during 36-month
follow-up increased by 36% for each mmol/l increment in
total cholesterol. This finding was independent of the age of
the patient, the presence of cachexia, and the etiology of the
CHF.
At first sight, it might appear that cholesterol might have
a deleterious effect in CHF. Cholesterol is a predictor of
increased morbidity and mortality (1,18) from coronary
artery disease, and coronary artery disease in the most
common cause of CHF in industrialized societies (19). The
occurrence of incident heart failure is reduced by long-term
treatment with cholesterol-reducing drugs (5).
There are few data on the effects of lipoprotein levels in
patients with established CHF. Vredevoe et al. (10) re-
ported lower total, LDL, and HDL cholesterol and triglyc-
eride levels in a group of 109 patients with severe CHF due
to dilated cardiomyopathy (but not patients with ischemic
heart disease). Richartz et al. (9) showed that low choles-
terol levels were associated with increased mortality in 45
patients undergoing left ventricular assist device implanta-
tion. In a small pilot study, we demonstrated that a
cholesterol level 5.2 mmol/l (200.8 mg/dl), which would
conventionally be considered to be a positive feature (20),
predicted a worse one-year event-free survival (21). Hor-
wich et al. (11) evaluated follow-up data in over 1,000
patients and found that patients in the lowest quintile of
total cholesterol had a twofold increase in relative risk
during five-year follow-up. This group also reported a
similar best cut-off value from ROC analysis at 4.9 mmol/l
(190 mg/dl).
Chronic heart failure is a metabolically demanding con-
dition. Resting energy consumption is increased (22,23),
and there is a general shift from anabolic to catabolic
processes (24). It may be that a higher cholesterol level
represents a greater metabolic reserve to deal with the CHF
syndrome. However, we believe that there may a specific
protective role for lipoproteins in CHF.
The origins of the immunologic activation seen in CHF
are not well understood. We have previously suggested that
a possible source is exposure to bacterial LPS or endotoxin
(25). Translocation of LPS across the intestinal wall, per-
Figure 2. Survival in the validation study related to the best predictive
value for serum cholesterol found in the derivation study. Log-rank p 
0.0011 for the difference between groups.
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haps due to bowel wall edema, leads to increased tumor
necrosis factor production by peripheral blood mononuclear
cells. In keeping with this suggestion, LPS is elevated in
patients with edematous CHF (25).
In this model, circulating lipoproteins are potentially of
beneficial importance by behaving as a sump for LPS at
times of increased exposure. Lipoproteins would contribute
to a reduction of LPS bioactivity and consequently lead to
lower levels of inflammatory cytokines. This may explain the
inverse correlation between cholesterol and sTNFR-1 in the
derivation study. In vitro (26) and in vivo (27) models of
endotoxemia in mice have demonstrated that lipoproteins
such as LDL (26), very-low-density lipoprotein (27), HDL
(28), lipoprotein(a) (29), triglycerides (30), and chylomi-
crons (27) can modulate the bioactivity of LPS. Lipoprotein
classes bind LPS in direct proportion to their plasma
cholesterol concentration (26). Furthermore, LDL
receptor-deficient mice with markedly increased plasma
cholesterol concentrations are protected against lethal en-
dotoxemia and severe gram-negative infections (29). The
most plausible mechanism by which lipoproteins bind to
LPS is by the formation of micelles (31).
This model suggests a beneficial role for lipoproteins in
patients with CHF and could explain the better survival of
patients with higher cholesterol levels. Additionally, choles-
terol levels reflect nutritional status, which might also have
a prognostic impact. In our studies, lipoprotein levels were
no different between patients with and without cachexia,
suggesting that cachexia in CHF may not be related major
nutritional abnormalities. The relationship between choles-
terol and survival was independent of the presence of
cachexia.
Cholesterol predicted survival, independent of the etiol-
ogy of heart failure. In our view, survival, in general, is a
result of a balance of risks. Cholesterol (particularly LDL) is
still likely to be a pro-atherosclerotic factor in CHF, but the
risk associated with this mechanism is unlikely to affect the
prognosis over the relatively short follow-up relevant to
heart failure. If cholesterol does limit (LPS-induced) pro-
duction of cytokines, particularly during phases of clinical
deterioration, then high levels of cholesterol may have a
strongly positive effect on survival. Thus, the balance of risk
attributable to cholesterol favors high levels in patients with
CHF, even with an ischemic etiology.
This proposed mechanism depends on the presence of
LPS as a pathogen. It is certainly present in patients with
severe heart failure, as well as in patients with sepsis and
liver cirrhosis (32). In sepsis, at least, higher lipoprotein
levels are related to a better outcome (33).
Study limitations. Our study cannot establish that low
cholesterol is the cause of increased mortality. In larger
cohorts of patients with standardized follow-up, it may be
possible in the future to analyze the interplay between
changes in lipoprotein levels, underlying treatment, changes
in body weight, and survival. We have reported on total
mortality, which may be the only indisputable and unbiased
end point in CHF patients. Our study was underpowered to
study the relationship between lipoprotein levels and the
frequency of events, such as nonfatal stroke or nonfatal
myocardial infarction. Patients with CHF who suffer a
stroke or myocardial infarction die earlier. We cannot see
how higher cholesterol levels could be related to much
better survival and more such events at the same time. The
study was not powered to exclude the presence of a
U-shaped relationship between cholesterol levels and sur-
vival. Interestingly, of 14 CHF patients with cholesterol
levels 8 mmol/l (308.9 mg/dl), none died during the first
Table 5. Predictors of Three-Year Survival in the Validation Study
Variable Hazard Ratio (95% CI) p Value Chi-square
Cachexia 5.4 (2.8–10.5) 0.0001 24.7
LVEF 0.94 (0.92–0.96) 0.0001 24.5
Peak VO2 0.90 (0.85–0.94) 0.0001 18.9
Etiology 0.67 (0.43–1.03) 0.06 3.4
NYHA class 2.16 (1.67–2.79) 0.0001 34.6
Age 1.02 (1.00–1.04) 0.06 3.4
Cholesterol 0.75 (0.63–0.90) 0.001 10.4
Total cholesterol 5.2 mmol/l 1.97 (1.30–2.97) 0.001 10.3
NYHA is treated as a continuous variable. Two sets of results for cholesterol are shown: cholesterol as a continuous variable and
cholesterol above or below the best predictive value calculated in the derivation study.
Abbreviations as in Tables 1 and 2.
Figure 3. Survival by etiology and cholesterol in the validation study.
Log-rank p  0.05 for comparison between high and low cholesterol in
nonischemic etiology and p  0.001 for ischemic etiology.
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12 months of follow-up. In this study, statin use seemed to
be associated with a lower mortality. We are unable to
analyze this finding further due to the small numbers of
patients taking statins (18% and 20% in the two patient
groups derivation and validation, respectively).
Conclusions. We have demonstrated a relationship be-
tween higher levels of cholesterol and increased survival in
patients with CHF, independent of age, etiology of CHF,
left ventricular function, and exercise capacity. The findings
have implications for the treatment of CHF. Many clini-
cians have applied the results of the clinical trials of
HMG-CoA reductase inhibitors to patients with CHF,
despite the fact that CHF patients were excluded from these
studies by design. The present data suggest the need for
caution. Reducing cholesterol may be deleterious in CHF,
but HMG-CoA reductase inhibitors may have other, more
important beneficial effects that outweigh this possible risk.
Controlled trials of statin therapy in patients with CHF are
needed.
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